Consistent with prior observations from both whole genome and exome sequencing in locally advanced and metastatic WD panNET [2], other notable mutations identified in the tumors of these 80 patients included mutations in the chromatin remodeling genes MEN1 (56%), DAXX (40%), ATRX (25%), and the mTOR pathway genes TSC2 (25%) and PTEN (13%), data is shown in S1 Fig and [31]. This evidence concerns the gene MTOR and Wilson disease.